Intrinsiqq
Kalaris Therapeutics, Inc. logo

Kalaris Therapeutics, Inc. Insider Trading

KLRS

Compare
Last 12 months

Insiders sold 13K and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. Chief Accounting Officer Brett R Hagen sold 13K on Mar 20, 100% of their stake, outside a plan. The last open-market buy by an executive or director was in Apr 2022.

Net open-market
−13K
0 buys · 1 sale
Under a 10b5-1 plan
0%
of the value sold
Insiders who bought / sold
0 / 1
executives and directors
Last open-market buy
Apr 2022
Apr 26, 2022

Get an email when KLRS's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • May 20
    Samsara Biocapital, L.p.
    Large holder · bought 244,300 at $4.83
    $1.18M
    1.9% of stake
  • Mar 20No plan
    Brett R Hagen
    Chief Accounting Officer · sold 1,915 at $6.72
    13K
    100% of stake
  • Dec 18, 2025
    Samsara Opportunity Fund, L.p.
    Large holder · bought 479,847 at $10.42
    $5M
    3.8% of stake
  • Mar 26, 2025No plan
    Brett R Hagen
    Chief Accounting Officer · sold 907 at $8.97
    8K
    32% of stake
  • Feb 21, 2025No plan
    Vikas Sinha
    See Remarks · sold 303 at $10.08
    3K
    <0.1% of stake
  • Feb 21, 2025No plan
    Brett R Hagen
    Chief Accounting Officer · sold 96 at $10.08
    $968
    3.3% of stake
  • Feb 21, 2025No plan
    Edward Miller
    General Counsel · sold 106 at $10.08
    1K
    0.5% of stake
  • Jan 23, 2025No plan
    Edward Miller
    General Counsel · sold 52 at avg $9.50
    $494
    0.2% of stake
  • Jan 23, 2025No plan
    Brett R Hagen
    Chief Accounting Officer · sold 36 at avg $9.50
    $342
    1.2% of stake
  • Jan 23, 2025No plan
    Vikas Sinha
    See Remarks · sold 129 at avg $9.50
    1K
    <0.1% of stake
  • Jan 10, 2025No plan
    Edward Miller
    General Counsel · sold 409 at $0.44
    $180
    <0.1% of stake
  • Jan 10, 2025No plan
    Brett R Hagen
    Chief Accounting Officer · sold 332 at $0.44
    $146
    0.5% of stake
  • Jan 10, 2025No plan
    Vikas Sinha
    See Remarks · sold 979 at $0.44
    $431
    <0.1% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch KLRS, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with KLRS

CompareIntrinsic value
ATYRAtyr Pharma Inc.
$3.82+3.52%10
WINTWindtree Therapeutics Inc.
$0.00-33.33%10
ZIVOZivo Bioscience Inc.
$5.50+0.00%0
VIVSVivoSim Labs, Inc.
$0.26-10.34%10
AIMAIM ImmunoTech Inc.
$0.11-4.50%25
ARTVArtiva Biotherapeutics Inc.
$3.78-1.31%10
IKTInhibikase Therapeutics Inc.
$1.31+0.38%10
CVMCel-Sci Corporation
$1.21-17.69%0

Spot a number that looks wrong? Check it in KLRS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing KLRS

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.